AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Handcycling training (3 × 30 min/week at 65% HRR for 7 weeks)
Number of subjects: 22
Study 27222003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 22
Study 25378931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-H2 water containing 7 ppm H2 (3.5 mg H2 in 500 mL water)
Number of subjects: 26
Study 25378931 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 26
Study 25378931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-H2 water
Number of subjects: 26
Study 21819594 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie treatment program
Number of subjects: 148
Study 21819594 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School treatment program
Number of subjects: 148
Study 19248539 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR group)
Number of subjects: 20
Study 19248539 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lens (IOL group)
Number of subjects: 20
Study 19248539 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CTR group to IOL group
Number of subjects: 20
Study 17217664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding until more than 4 months of age, followed by partially hydrolyzed formula (pHF), combined with solid foods avoidance until 4 months, and avoidance of egg, fish, and shrimp until 12 months.
Number of subjects: 46
Study 17217664 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding for less than 4 months or bottle feeding with cow's milk-based formula, introduction of egg yolk at 4 months and egg white at 6 months, with no dietary avoidance.
Number of subjects: 46
Study 17217664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (breastfeeding and dietary avoidance)
Number of subjects: 46
Study 17217664 — intervention group
Group type: COMPARATOR
Intervention: Control group (less breastfeeding and no dietary avoidance)
Number of subjects: 46
Study 14687092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 16
Study 14687092 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 16
Study 11593067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics, digoxin, angiotensin‐converting enzyme inhibitors, beta‐blockers; specific dosages and durations not available.
Number of subjects: 0
Study 11593067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective, randomized trials; specific details not available.
Number of subjects: 0
Study 8988914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A dosing
Number of subjects: 207
Study 8988914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 7903966 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (intervention group)
Number of subjects: 85
Study 7903966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 85
Study 3121055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 48
Study 3121055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strengthening exercises
Number of subjects: 48
Study 3121055 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 122696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme group (mutanase and protease)
Number of subjects: 60
Study 122696 — intervention group
Group type: COMPARATOR
Intervention: Steradent group
Number of subjects: 60
Study 122696 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 30709402 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention designed to reduce exposure to second-hand smoke; details on dosage and duration not specified.
Number of subjects: 0
Study 30709402 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 27145447 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 277
Study 27145447 — intervention group
Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 277
Study 26405990 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkvetch root
Number of subjects: 0
Study 26405990 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical therapy
Number of subjects: 0
Study 23280141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (125 mg Bid, n=11)
Number of subjects: 21
Study 23280141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 21
Study 22142580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) for mesh fixation
Number of subjects: 40
Study 22142580 — intervention group
Group type: COMPARATOR
Intervention: Titanium tacks for mesh fixation
Number of subjects: 40
Study 19744614 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP at 0.02 microg/kg/min from the start of cardiopulmonary bypass
Number of subjects: 504
Study 19744614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no hANP)
Number of subjects: 504
Study 17196159 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 56
Study 17196159 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 56
Study 17196159 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 56
Study 15651488 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride daily for 7 years
Number of subjects: 0
Study 11680643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (early caries risk assessment and preventive care)
Number of subjects: 167
Study 11680643 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (historical control)
Number of subjects: 167
Study 11680643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 167
Study 11680643 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 167
Study 9470059 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (75 mg/day) plus losartan (25 mg/day)
Number of subjects: 44
Study 9470059 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75 mg/day) plus placebo
Number of subjects: 44
Study 7911029 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 100 mg
Number of subjects: 60
Study 7911029 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 200 mg
Number of subjects: 60
Study 7911029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 2451383 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment, 10 systemic treatments
Number of subjects: 0
Study 2451383 — intervention group
Group type: COMPARATOR
Intervention: Mechlorethamine (HN2) treatment, 3 weeks duration
Number of subjects: 0
Study 31994641 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Prevention intervention
Number of subjects: 0
Study 31994641 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion condition
Number of subjects: 0
Study 29742924 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (POL)
Number of subjects: 30
Study 29742924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Policosanol (POL) and Pentoxifylline (PTX)
Number of subjects: 30
Study 29742924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study 29742924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29742924 — intervention group
Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 30
Study 28904061 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (4 decaffeinated GTE capsules containing 1,315 mg total catechins, including 843 mg EGCG for 12 months)
Number of subjects: 1075
Study 28904061 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation
Number of subjects: 1075
Study 28904061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 26231288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks
Number of subjects: 452
Study 26231288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab every 4 weeks
Number of subjects: 452
Study 26231288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 23393057 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 45
Study 23393057 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 45
Study 21159789 — intervention group
Group type: COMPARATOR
Intervention: 3.4 g/d EPA+DHA
Number of subjects: 26
Study 21159789 — intervention group
Group type: COMPARATOR
Intervention: 0.85 g/d EPA+DHA
Number of subjects: 26
Study 21159789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18500088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 66
Study 18500088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 66
Study 16918535 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde reperfusion via vena cava
Number of subjects: 132
Study 16918535 — intervention group
Group type: COMPARATOR
Intervention: Standard reperfusion with anterograde simultaneous arterial and portal reperfusion
Number of subjects: 132
Study 14971189 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and cycling on indoor exercise machines at a moderate intensity until 400 kcals expended, five times a week (short-bout programme)
Number of subjects: 30
Study 14971189 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and cycling on indoor exercise machines expending 1,000 kcal per session on two days a week (long-bout programme)
Number of subjects: 30
Study 11738778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (HG) - mild hypothermia induced by a helmet device
Number of subjects: 30
Study 11738778 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (NG)
Number of subjects: 30
Study 9421348 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg daily for weeks 2-10, flexible dosing 100-200 mg daily for weeks 11-26)
Number of subjects: 107
Study 9421348 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 mg daily for weeks 2-10, flexible dosing 75-150 mg daily for weeks 11-26)
Number of subjects: 107
Study 9421348 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 107
Study 9421348 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 107
Study 8098588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.12 mg.kg‐1; ED95 x 2)
Number of subjects: 18
Study 8098588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.4 mg.kg‐1; ED95 x 2)
Number of subjects: 18
Study 8098588 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 18
Study 8098588 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 18
Study 3534583 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + TAM (10 mg three times daily for 1 yr)
Number of subjects: 1650
Study 3534583 — intervention group
Group type: COMPARATOR
Intervention: RT (postoperative radiotherapy)
Number of subjects: 1650
Study 3534583 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + TAM
Number of subjects: 1650
Study 3534583 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 1650
Study 29941309 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective communication (supportive comments)
Number of subjects: 60
Study 29941309 — intervention group
Group type: COMPARATOR
Intervention: Standard communication (no supportive comments)
Number of subjects: 60
Study 29941309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (affective and standard communication)
Number of subjects: 60
Study 27895700 — intervention group
Group type: EXPERIMENTAL
Intervention: BASNEF model intervention with GATHER counselling steps
Number of subjects: 124
Study 27895700 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study 25010236 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour BLS course based on computer‐assisted presentations (E1)
Number of subjects: 104
Study 25010236 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour BLS course practicing BLS algorithm in pairs (E2)
Number of subjects: 104
Study 25010236 — intervention group
Group type: COMPARATOR
Intervention: Self-learning BLS algorithm (C)
Number of subjects: 104
Study 22011096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016-inch coaxial superelastic nickel-titanium (NiTi)
Number of subjects: 24
Study 22011096 — intervention group
Group type: COMPARATOR
Intervention: 0.016-inch superelastic nickel-titanium (NiTi)
Number of subjects: 24
Study 19929191 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 30,000 U intravenous every 48 hours for 3 doses
Number of subjects: 80
Study 19929191 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 80
Study 19929191 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) with statins
Number of subjects: 80
Study 19929191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18189169 — intervention group
Group type: EXPERIMENTAL
Intervention: African American elders
Number of subjects: 0
Study 18189169 — intervention group
Group type: COMPARATOR
Intervention: Control for reading level achievement
Number of subjects: 0
Study 16814646 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3491
Study 16814646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491
Study 14682110 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim [Neupogen])
Number of subjects: 0
Study 14682110 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF, sargramostim [Leukine])
Number of subjects: 0
Study 11027376 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniplate fixation with intermaxillary fixation for 6 weeks
Number of subjects: 30
Study 11027376 — intervention group
Group type: COMPARATOR
Intervention: Bicortical screw fixation with immediate postoperative function
Number of subjects: 30
Study 8682519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D auditory display
Number of subjects: 0
Study 8682519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bird's-eye-view radar display
Number of subjects: 0
Study 8682519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D auditory display + Bird's-eye-view radar display (simultaneously)
Number of subjects: 0
Study 8682519 — intervention group
Group type: COMPARATOR
Intervention: Tactical display only
Number of subjects: 0
Study 1632006 — intervention group
Group type: EXPERIMENTAL
Intervention: District psychiatric treatment after discharge
Number of subjects: 0
Study 1632006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6716990 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = -4
Number of subjects: 36
Study 6716990 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = 0
Number of subjects: 36
Study 6716990 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = +2
Number of subjects: 36
Study 31493361 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to a new diabetologist
Number of subjects: 100
Study 31493361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transition)
Number of subjects: 100
Study 28930912 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (5 mg twice daily) for 96 hours
Number of subjects: 70
Study 28930912 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 70
Study 28930912 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 70
Study 27791067 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 954
Study 27791067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 954
Study 24184410 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g of glucose
Number of subjects: 0
Study 24184410 — intervention group
Group type: COMPARATOR
Intervention: Sucralose placebo
Number of subjects: 0
Study 22180438 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length compression elastic stockings (CES)
Number of subjects: 267
Study 22180438 — intervention group
Group type: COMPARATOR
Intervention: Below-knee compression elastic stockings (CES)
Number of subjects: 267
Study 20309434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 22
Study 20309434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17413473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan device (Medtronic Sofamor Danek)
Number of subjects: 20
Study 17413473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige LP device (Medtronic Sofamor Danek)
Number of subjects: 20
Study 17413473 — intervention group
Group type: COMPARATOR
Intervention: PCM device (Cervitech)
Number of subjects: 20
Study 17413473 — intervention group
Group type: COMPARATOR
Intervention: Prodisc-C device (Synthes Spine)
Number of subjects: 20
Study 17413473 — intervention group
Group type: COMPARATOR
Intervention: PCM and Prodisc-C devices
Number of subjects: 20
Study 17413473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan and Prestige LP devices
Number of subjects: 20
Study 15526113 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 U botulinum toxin injected into the internal sphincter
Number of subjects: 100
Study 12392872 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (new procedure)
Number of subjects: 619
Study 12392872 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (standard procedure)
Number of subjects: 619
Study 10049056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 359
Study 10049056 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 359
Study 10049056 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched unrelated donor allograft
Number of subjects: 359
Study 10049056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT)
Number of subjects: 359
Study 10049056 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 359
Study 10049056 — intervention group
Group type: COMPARATOR
Intervention: Overall survival rate
Number of subjects: 359
Study 10049056 — intervention group
Group type: COMPARATOR
Intervention: Disease-free survival
Number of subjects: 359
Study 10049056 — intervention group
Group type: COMPARATOR
Intervention: Length of first remission
Number of subjects: 359
Study 7583868 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (60 mg daily for 7 days)
Number of subjects: 20
Study 7583868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2153735 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg five times daily for 5 days
Number of subjects: 174
Study 2153735 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 174
Study 6794909 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM (hexamethylmelamine, doxorubicin, and methotrexate)
Number of subjects: 154
Study 6794909 — intervention group
Group type: COMPARATOR
Intervention: CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 154
Study 6794909 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (combined HAM and CAMP)
Number of subjects: 154
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being (measured by the FACIT-Sp scale)
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment to a stoma (measured by the Ostomy Adjustment Scale)
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (measured by the Stoma Quality of Life Scale)
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between spiritual well-being and quality of life
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between spiritual well-being and adjustment to a stoma
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between quality of life and adjustment to a stoma
Number of subjects: 95
Study 31364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting quality of life
Number of subjects: 95
Study 28609349 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEAL IMPLANT Core Study
Number of subjects: 502
Study 28609349 — intervention group
Group type: COMPARATOR
Intervention: Other breast implant trials (MemoryShape, Allergan 410, Sientra Core Studies)
Number of subjects: 502
Study 26773962 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-type (AcuLoc(TM), Group A)
Number of subjects: 64
Study 26773962 — intervention group
Group type: COMPARATOR
Intervention: Proximal-type (VariAx(TM), Group V)
Number of subjects: 64
Study 24635701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 59
Study 24635701 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study 23173326 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC hydrogel with EGCG
Number of subjects: 64
Study 23173326 — intervention group
Group type: COMPARATOR
Intervention: CMC hydrogel (control group)
Number of subjects: 64
Study 19803599 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist behaviors (teaching, focusing on strengths, making reinforcing statements, problem solving, dealing with practical family needs)
Number of subjects: 0
Study 19803599 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist behaviors
Number of subjects: 0
Study 19803599 — intervention group
Group type: COMPARATOR
Intervention: Caregiver race, financial hardship, and therapist-caregiver racial match
Number of subjects: 0